ANAPTYSBIO, INC. Increase (Decrease) in Deferred Income Taxes
ANAPTYSBIO, INC. (ANAB) reported Increase (Decrease) in Deferred Income Taxes of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-05-12
- ANAPTYSBIO, INC. increase (decrease) in deferred income taxes for the quarter ending 2026-03-31 was $0.00.
- ANAPTYSBIO, INC. increase (decrease) in deferred income taxes for the quarter ending 2025-03-31 was -$3.54M.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month |
|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 |
| 2025-03-31 | -$3.54M 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |